检索结果 - Goodenow, Bob

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

    HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors 由 Shojaei, Farbod, Goodenow, Bob, Lee, Gloria, Kabbinavar, Fairooz, Gillings, Mireille

    出版 2022
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:
  2. 2
    The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

    The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors 由 Bissonnette, Reid P., Cesario, Rosemary M., Goodenow, Bob, Shojaei, Farbod, Gillings, Mireille

    出版 2021
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:

检索工具: